Plans to start a new Phase II study of SER-109, branded ECOSPOR III, have been announced by Seres Therapeutics Inc (NASDAQ:MCRB). The drug is meant to treat patients who are suffering from an infection known as clostridium difficile. This came about following a meeting with the Food and Drug Administration.
“Following the completion of our comprehensive analyses of the SER-109 study results, we had very productive discussions with the FDA, in which we gained highly positive and constructive guidance on further SER-109 clinical development,” Seres Therapeutics Inc (NASDAQ:MCRB) chairman and chief executive officer, Roger Pomerantz, said.
pikselstock/Shutterstock.com
Pioneering A Microbiome Therapeutic
If the drug gets the approval of the FDA, it will become the pioneering microbiome therapeutic in the market. The gastrointestinal drug serves as fecal transplant alternative and has sometimes been referred to as a ‘poop pill’, though Seres Therapeutics has refused to encourage such a nickname. Perhaps, though, it would be fitting and encourage sales.
The green-light from the FDA to have the study carried out follows the case of the earlier trial having gone wrong. This happened after certain participants were misdiagnosed, as they were not suffering from clostridium difficile. Another problem that was witnessed was that some of the participants were not given an adequate SER-109 dose.
More Accuracy, More Participants
Some of the changes that Seres Therapeutics Inc (NASDAQ:MCRB) will be making in the new trial include measuring the infection using a mechanism that is more accurate. Patients will also be given a bigger dose, at least 10 times higher. The number of participants in the trial will also increase from 89 to 320 patients.
The U.S. Food and Drug Administration has also come to an agreement to designate the trial a pivotal study in the event that the gastrointestinal drug proves to be effective and is able to meet the other regulatory conditions.
Currently, two designations have been given to SER-109 by the FDA and these could put the drug on the path of being quickly approved. These include being designated as a therapy that offers a potential breakthrough and orphan drug status.
On Thursday, shares of Seres Therapeutics Inc (NASDAQ:MCRB) jumped by 37.11% to close the day at $12.71.
Follow Seres Therapeutics Inc. (NASDAQ:MCRB)
Follow Seres Therapeutics Inc. (NASDAQ:MCRB)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Note: This article is written by Adam Russell and was originally published at Market Exclusive.
Subscribe to Insider Monkey's Free Daily Newsletter and Join 80K+ Readers
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Warren Buffett never mentions this but he is one of the first hedge fund managers who unlocked the secrets of successful stock market investing. He launched his hedge fund in 1956 with $105,100 in seed capital. Back then they weren’t called hedge funds, they were called “partnerships”. Warren Buffett took 25% of all returns in excess of 6 percent.
For example S&P 500 Index returned 43.4% in 1958. If Warren Buffett’s hedge fund didn’t generate any outperformance (i.e. secretly invested like a closet index fund), Warren Buffett would have pocketed a quarter of the 37.4% excess return. That would have been 9.35% in hedge fund “fees”.
Actually Warren Buffett failed to beat the S&P 500 Index in 1958, returned only 40.9% and pocketed 8.7 percentage of it as “fees”. His investors didn’t mind that he underperformed the market in 1958 because he beat the market by a large margin in 1957. That year Buffett’s hedge fund returned 10.4% and Buffett took only 1.1 percentage points of that as “fees”. S&P 500 Index lost 10.8% in 1957, so Buffett’s investors actually thrilled to beat the market by 20.1 percentage points in 1957.
Between 1957 and 1966 Warren Buffett’s hedge fund returned 23.5% annually after deducting Warren Buffett’s 5.5 percentage point annual fees. S&P 500 Index generated an average annual compounded return of only 9.2% during the same 10-year period. An investor who invested $10,000 in Warren Buffett’s hedge fund at the beginning of 1957 saw his capital turn into $103,000 before fees and $64,100 after fees (this means Warren Buffett made more than $36,000 in fees from this investor).
As you can guess, Warren Buffett’s #1 wealth building strategy is to generate high returns in the 20% to 30% range.
We see several investors trying to strike it rich in options market by risking their entire savings. You can get rich by returning 20% per year and compounding that for several years. Warren Buffett has been investing and compounding for at least 65 years.
So, how did Warren Buffett manage to generate high returns and beat the market?
In a free sample issue of our monthly newsletter we analyzed Warren Buffett’s stock picks covering the 1999-2017 period and identified the best performing stocks in Warren Buffett’s portfolio. This is basically a recipe to generate better returns than Warren Buffett is achieving himself.
You can enter your email below to get our FREE report. In the same report you can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12-24 months. We initially share this idea in October 2018 and the stock already returned more than 150%. We still like this investment.
Free Report Reveals
Warren Buffet's Secret Recipe
Our Price: $199FREE
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
